ArticleFrontiers in oncology2026
LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stereotactic body radiotherapy (SBRT) combined with lenvatinib and tislelizumab has shown potential activity in advanced hepatocellular carcinoma (HCC), but early treatment failure (ETF) remains common. We developed an exploratory model to estimate ETF, defined as radiologically confirmed progressive disease (PD) or all-cause death within 6 months after treatment initiation. Methods: This single-center retrospective study included advanced HCC patients treated with the triple regimen from June 2021 to June 2024. Baseline clinical, imaging, and hematological variables were analyzed. LASSO regression with 10-fold cross-validation was used for feature selection. Restricted cubic splines assessed linearity, and λ.1se was examined as a sensitivity analysis. A multivariable logistic regression model was presented as a nomogram. Discrimination, calibration, and decision curve analysis (DCA) were evaluated, with 1000-resample bootstrap internal validation repeating the modeling pipeline. Results: Among 118 patients, 33 (27.9%) experienced ETF; 28 had radiologically confirmed PD and 5 died without prior documented PD. At λ.min, LASSO selected maximum tumor diameter, Vp4 portal vein tumor thrombosis (PVTT), baseline systemic immune-inflammation index (SII), ALBI score, and log10-transformed alpha-fetoprotein (AFP). Under λ.1se, four predictors were retained, with SII excluded. The final model had an apparent ROC-AUC of 0.903 and an optimism-corrected ROC-AUC of 0.866. Calibration showed acceptable agreement between predicted and observed risks. DCA suggested net benefit over an exploratory threshold range of approximately 0.10-0.50, which should not be interpreted as a validated treatment-switching threshold. Conclusion: The nomogram showed promising internal discrimination for estimating 6-month ETF risk in advanced HCC patients receiving SBRT, lenvatinib, and tislelizumab. Given the modest sample size and single-center design, the model remains exploratory and hypothesis-generating. External multicenter validation is required before clinical implementation or use for treatment selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.